IB
IBO.US Impact BioMedical, Inc.
- Market cap
- USD 44.4M
- P/E
- 0.4x
- P/B
- 4.39x
- ROE
- -47.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is IBO.US undervalued?
Graham numberThe Graham number of Impact BioMedical, Inc. cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Impact BioMedical, Inc. fundamental analysis
No fundamental analysis for Impact BioMedical, Inc. yet.
Impact BioMedical, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that …
Full company profileImpact BioMedical, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Impact BioMedical, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | - | - | 0.00 | - | 50.0K | 50.0K | 1.03M | 1.62M | 32.0K | 41.3K |
| Gross Profit | - | - | - | - | 50.0K | 50.0K | -1.12M | 1.62M | -392K | 32.0K |
| Operating Income | 64.0K | -33.9K | -680K | -897K | -3.40M | -3.40M | -4.03M | -28.8M | -4.27M | -4.85M |
| EBITDA | 64.0K | -33.9K | 638.00 | -897K | -6.30M | -6.30M | -2.84M | -22.6M | -12.5M | -3.70M |
| Net Income | -408K | -98.1K | -590K | -597K | -7.05M | -7.05M | -4.34M | -24.7M | -11.8M | -4.84M |
| EPS | -0.04 | -0.01 | -0.05 | -0.66 | -7.74 | -7.74 | -0.91 | -7.47 | -4.74 | -0.57 |
| Balance Sheet | ||||||||||
| Total Assets | 321K | 217K | 117K | 48.1M | 56.4M | 46.5M | 44.6M | 20.3M | 17.4M | 16.4M |
| Total Liabilities | 25.4K | 20.1K | 21.7K | 6.32M | 16.5M | 13.8M | 16.4M | 13.1M | 1.85M | 3.06M |
| Shareholders' Equity | 295K | 197K | 94.9K | 37.9M | 36.6M | 29.6M | 25.2M | 4.26M | 12.6M | 10.1M |
| Cash & Short-term Investments | 51.9K | 205K | 97.7K | 72.3K | 46.0K | 2.00K | 1.00K | 2.00M | 3.00K | 21.0K |
| Total Debt | - | - | - | 1.06M | 12.5M | 9.99M | 12.1M | 8.88M | - | - |
| Cash Flow | ||||||||||
| Operating Cash Flow | -320K | -72.0K | -122K | -899K | -2.24M | -2.24M | -2.85M | -5.64M | -1.89M | 22.7K |
| Capital Expenditure | 0.00 | 0.00 | 1.53K | 3.00 | 276K | 276K | 18.0K | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | -320K | -72.0K | -124K | -899K | -2.52M | -2.52M | -2.87M | -5.64M | -1.89M | 22.7K |
| Ratios | ||||||||||
| ROE | -138.3% | -49.8% | -621.9% | -1.6% | -19.3% | -23.9% | -17.2% | -580.1% | -93.9% | -47.8% |
| ROA | -127.3% | -45.2% | -506.0% | -1.2% | -12.5% | -15.2% | -9.7% | -121.8% | -68.0% | -29.5% |
| Net Profit Margin | - | - | - | - | -14,102.0% | -14,102.0% | -421.0% | -1,525.3% | -36,993.8% | -11,712.9% |
| Debt to Equity | - | - | - | 0.03x | 0.34x | 0.34x | 0.48x | 2.08x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Impact BioMedical, Inc. dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | USD 410K | 0.45 | - |
| 2021 | USD 410K | 0.45 | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 79:1000 on Sep 23, 2026.
Who owns Impact BioMedical, Inc.
- Insiders 88.51%
- Institutions 3.61%
- Public & others 7.89%
- Shares outstanding 8.64M
- Free float 845K
Impact BioMedical, Inc. company profile
- Company name
- Impact BioMedical, Inc.
- Ticker
- IBO.US
- Exchange
- USA Stocks
- Listed since
- Sep 16, 2024
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 2
- Fiscal year end
- December
- Address
- 1400 Broadfield Blvd., Houston, TX, United States, 77084
- Phone
- 281 415 6576
- Website
- impactbiomedinc.com
About Impact BioMedical, Inc.
Impact BioMedical Inc. discovers, develops, and commercializes products and technologies to address unmet needs in human healthcare and wellness for specialty biopharmaceuticals, antivirals, antimicrobials, consumer healthcare, and wellness products in the United States. The company provides Linebacker, a platform of small molecule electrophilically enhanced polyphenol compounds with application in oncology, inflammatory disorders, and neurology; and Laetose technology that is derived from a unique combination of sugar and inositol, which can inhibit the inflammatory and metabolic response of sugar alone. It also develops functional fragrance formulation, a suite of functional fragrances containing specialized botanical ingredients with application as an antimicrobial, and as an additive in insect repellents, detergents, lotions, shampoo, fabrics, and other substances. In addition, the company develops Equivir/Equivir G technology, a novel blend of polyphenols, which have demonstrated antiviral effects for use as health supplements and medications. Further, it is developing 3F (functional fragrance formulation), a formulation of botanical ingredients. Impact BioMedical Inc. was incorporated in 2018 and is based in Houston, Texas. Impact BioMedical Inc. operates as a subsidiary of DSS BioHealth Security, Inc.
Impact BioMedical, Inc. management
3- Mr. Frank D. Heuszel Esq., J.D.Chairman & CEO · born 1956
- Mr. Todd D. Macko C.P.A.CFO, Secretary & Treasurer · born 1973
- Mr. Mark J. SuseckChief Operating Officer · born 1964